<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01267162</url>
  </required_header>
  <id_info>
    <org_study_id>IN-US-174-0156</org_study_id>
    <nct_id>NCT01267162</nct_id>
  </id_info>
  <brief_title>Long-term Study on Anti-HBV Effect of Tenofovir and Resistance Surveillance in Asian-American Adult Patients</brief_title>
  <official_title>Long-term Observational Study on Anti-HBV Effect of Tenofovir Disoproxil Fumarate (TDF) and Resistance Surveillance in Asian-American Adult Patients Formerly Participating Gilead 123 Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Procare PLLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Procare PLLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IV, open-label, single-arm, 96 week community-based observational study&#xD;
      evaluating the antiviral efficacy, safety, and tolerability of TDF in HBV mono-infected&#xD;
      Asian-American adults who had completed 48 week treatment with Tenofovir in Gilead 174-0123&#xD;
      study. The primary objective of this study is to evaluate the long-term antiviral efficacy of&#xD;
      tenofovir DF 300 mg once daily in these patients. The secondary objectives are to evaluate&#xD;
      the safety and tolerability of TDF including the biochemical and virological responses to&#xD;
      TDF, the incidence of drug resistance mutations in these patients The duration of treatment&#xD;
      in this study is total of three Years (144 weeks) on TDF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HBV DNA suppression</measure>
    <time_frame>in three years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>safety use of TDF</measure>
    <time_frame>in three years</time_frame>
    <description>including elevation of creatine or decrease in GFR, TDF resistance</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">31</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>TDF Treatment</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        adult infected with chronic hepatitis B&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, Asian-American, who have participated and completed the study, qualify&#xD;
             the following criteria, and remain on TDF treatment without severe treatment-related&#xD;
             AEs, and with available retrospective lab results as summarized in Appendix 2.&#xD;
&#xD;
          -  18 through 75 years of age, inclusive&#xD;
&#xD;
          -  Willing to participate in the present study and able to provide written informed&#xD;
             consent&#xD;
&#xD;
          -  Continuation of HBV treatment is indicated. That is for HBeAg-positive subjects, HBeAg&#xD;
             remain positive or HBeAg becomes negative but still has detectable DNA by the PCR&#xD;
             method; and for HBeAg-negative subjects, HBV DNA is either detectable or undetectable&#xD;
             by the PCR method&#xD;
&#xD;
          -  No clinical or virologic evidence of anti-HBV resistance to TDF treatment at the time&#xD;
             of entering tests (i.e., TDF treatment week 48 lab tests by the 123 study)&#xD;
&#xD;
          -  Estimated glomerular filtration rate (creatinine clearance) ≥ 60 mL/min/1.73m2 by the&#xD;
&#xD;
        Cockcroft-Gault equation:&#xD;
&#xD;
        (140-age in years) (body weight [kg]) (72) (serum creatinine [mg/dl]) [Note: multiply&#xD;
        estimated rate 0. by 85 for women; use actual body weight]&#xD;
&#xD;
        • Adequate hematologic function (absolute neutrophil count ≥ 1,500/mm3; hemoglobin ≥ 10.0&#xD;
        g/dL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women, and women who are breast feeding or who believe they may wish to&#xD;
             become pregnant during the course of the study.&#xD;
&#xD;
          -  Males and females of reproductive potential who are not willing to use an effective&#xD;
             method of contraception during the study. For males, condoms should be used and for&#xD;
             females, a barrier contraception method should be used in combination with one other&#xD;
             form of contraception.&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Decompensated liver disease defined as direct (conjugated) bilirubin ≥ 1.2 ULN; PT ≥&#xD;
             1.2 ULN, platelets ≤ 150,000/mm3, or serum albumin ≤ 3.5 g/dL&#xD;
&#xD;
          -  Prior history of clinical hepatic decompensation (e.g., ascites, jaundice,&#xD;
             encephalopathy) or variceal hemorrhage&#xD;
&#xD;
          -  Serum α-fetoprotein ≥ 50 ng/mL&#xD;
&#xD;
          -  Evidence of hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  Co-infection with HIV, HCV, or HDV&#xD;
&#xD;
          -  History of significant renal disease (e.g., nephrotic syndrome, renal dysgenesis,&#xD;
             polycystic kidney disease, congenital nephrosis, acute tubular necrosis, other renal&#xD;
             disease)&#xD;
&#xD;
          -  History of significant bone disease (e.g., osteomalacia, chronic osteomyelitis,&#xD;
             osteogenesis imperfecta, osteochondroses, multiple bone fractures)&#xD;
&#xD;
          -  Significant cardiovascular, pulmonary or neurological disease&#xD;
&#xD;
          -  Evidence of a gastrointestinal malabsorption syndrome that may interfere with&#xD;
             absorption of orally administered medications&#xD;
&#xD;
          -  History of solid organ or bone marrow transplantation&#xD;
&#xD;
          -  Ongoing therapy with any of the following: Nephrotoxic agents&#xD;
&#xD;
          -  Parenteral aminoglycoside antibiotics (e.g., gentamicin, tobramycin, amikacin)&#xD;
&#xD;
          -  Cidofovir&#xD;
&#xD;
          -  Cisplatin&#xD;
&#xD;
          -  Foscarnet&#xD;
&#xD;
          -  IV amphotericin B&#xD;
&#xD;
          -  IV pentamidine&#xD;
&#xD;
          -  Oral or IV ganciclovir&#xD;
&#xD;
          -  Cyclosporine&#xD;
&#xD;
          -  Tacrolimus&#xD;
&#xD;
          -  IV vancomycin&#xD;
&#xD;
          -  Chronic daily non-steroidal anti-inflammatory drug therapy&#xD;
&#xD;
          -  Competitors of renal excretion (e.g., probenecid) Systemic chemotherapeutic agents&#xD;
&#xD;
          -  Systemic corticosteroids&#xD;
&#xD;
          -  Interleukin-2 (IL-2) and other immunomodulating agents&#xD;
&#xD;
        Investigational agents (except with the expressed approval of the lead investigators)&#xD;
        Administration of any of the above medications must be discontinued at least 30 days prior&#xD;
        to the Baseline Visit and for the duration of the study period.&#xD;
&#xD;
          -  Known hypersensitivity to the study drugs, the metabolites or formulation excipients&#xD;
&#xD;
          -  Any other condition (including alcohol or substance abuse) or prior therapy that, in&#xD;
             the opinion of the Investigators, would make the subject unsuitable for the study or&#xD;
             unable to comply with dosing requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asian Pacific Liver Center of St. Vincent Medical Center</name>
      <address>
        <city>LA</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jose Gastroenterology</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Calvin Pan's Flushing Office</name>
      <address>
        <city>Flushing, Queens</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dreamworks Endoscopy</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiaoli Ma, PC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>December 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2010</study_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CHB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

